

Bone marrow-derived liver-committed stem cell mobilization by G-CSF to enhance liver regeneration after hepatectomy

Submission date 22/12/2015	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/01/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 07/01/2016	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Liver tumors usually require surgical treatment. Surgery to remove part of the liver (partial hepatectomy) is commonly performed. After hepatectomy regeneration of the liver is very important to maintain liver function. Stem cells from the bone marrow could migrate from the bloodstream to the liver and contribute to liver regeneration. Granulocyte-colony stimulating factor (G-CSF) can be given to patients to stimulate the bone marrow to produce and release the stem cells. The aim of this study is to find out whether infusing G-CSF before partial hepatectomy mobilizes patients' stem cells and improves liver recovery.

Who can participate?

Patients aged 18 to 75 with benign or malignant liver tumors and undergoing partial hepatectomy.

What does the study involve?

Participants are randomly allocated to one of two groups. In one group participants are treated with G-CSF every day in the morning for five consecutive days before undergoing partial hepatectomy. In the other group participants are treated with saline (salt solution) in the same manner before undergoing partial hepatectomy. Blood samples are collected from the two groups to investigate the presence of stem cells in the blood. The results are compared with the results obtained from healthy volunteers. All patients are monitored daily by physical examination and laboratory tests. CT scans are performed to evaluate liver volume, tumor mass and liver recovery.

What are the possible benefits and risks of participating?

The benefit would be enhanced remnant liver recovery after hepatectomy. G-CSF has been used with no harm for more than 30 years.

Where is the study run from?

1. Clinic Hospital, Barão Geraldo (Brazil)
2. Haematology Hemotherapy Centre, Barão Geraldo (Brazil)

When is the study starting and how long is it expected to run for?
August 2008 to July 2015

Who is funding the study?

1. Norrbacka-Eugenia Foundation (Sweden)
2. Foundation Sunnerdahls Disability Fund (Sweden)
3. Promobilia Foundation (Sweden)

Who is the main contact?

1. Dr Ângela Luzo (scientific)
2. Dr Ilka Boin (scientific)

Contact information

Type(s)

Scientific

Contact name

Dr Ângela Luzo

ORCID ID

<http://orcid.org/0000-0002-1422-9119>

Contact details

Como chegar ao Hemocentro
Rua Carlos Chagas, 480
Campinas
Brazil
13083-970

Type(s)

Scientific

Contact name

Dr Ilka Boin

ORCID ID

<http://orcid.org/0000-0002-1165-2149>

Contact details

Cidade Universitária
Rua Carlos Chagas 420
Campinas
Brazil
13083-878

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

G-CSF mobilization in the pre-operative period to enhance remnant liver recovery after hepatectomy: a randomised controlled trial

Study objectives

Pre operative G-CSF mobilization might recruit bone marrow-derived liver committed stem cells (BMDLCSC), immunophenotyped as CD34+/Lin-/CXCR4+/SDF1+ stem cells, improving remnant liver recovery in patients undergoing extensive PH.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Ethics Committee of the Faculty of Medical Sciences (State University of Campinas), 15/12/2009, ref: 996/2008
2. Brazilian National Ethics Committee (CONEP), 29/01/2010, ref: 061/2010

Study design

Prospective double-blind randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Controlled primary neoplasia disease

Interventions

The presence of bone marrow-derived liver committed stem cells, immunophenotyping as D34+ /Lin-/CXCR4+/SDF1+ stem cells, were previously investigated by flow cytometry in the peripheral blood of 9 adult healthy volunteers, with the same median age of the eligible patients, in order to be used as healthy normal controls of these cells. All patients were hospitalized in the Liver Unit one day prior to mobilization or infusion of NaCl 0.9%. In the intervention group bone marrow stem cells mobilization was induced by G-CSF (Granulokyn, Roche), administered via subcutaneous 10 µg/kg every day, in the morning during five consecutive days. The control group received subcutaneous NaCl 0.9% in the same volume as G-CSF in the same manner (every day, in the morning during five consecutive days). Before the beginning of the mobilization protocol, blood samples were collected from the two groups to perform flow cytometry analyses to investigate the previous presence of BMDLCS (CD34+ /Lin-/CXCR4+/SDF1 + stem cells) in the peripheral blood. The results were compared with the ones obtained from healthy donor controls. All patients were submitted to PH on the 5th day of G-CSF /NaCl 0.9% mobilization, and monitored daily by physical examination and laboratory tests. Abdominal CT was performed to evaluate hepatic volume, the amount of tumor mass pre partial liver resection and in the post surgery period, and on day 10, 30 and 60 to evaluate the remnant liver growth.

Intervention Type

Procedure/Surgery

Primary outcome measure

The effectiveness of recruitment and release of bone marrow-derived liver-committed stem cells to the peripheral blood by granulocyte colony stimulating factor (G-CSF) bone marrow mobilization at improving remnant liver recovery in patients undergoing extensive liver resections.

The recruitment and release of bone marrow-derived liver-committed stem cells was measured by flow cytometry analysis with specific labeled antibodies: IgG FITC/ IgG PE; CD45 Percp; CD14 FITC CD33 APC; CD34 APC; CD19 FITC ; CD3 PE; cySDF1 Alexa fluor 488; CD184 PE(CXCR4); cyCD184 PE, disposed for the analyses as: cySDF1 Alexa fluor 488/ CD184 PE/ CD45 Percp/ CD34 APC; CD14 FITC/ CD34 PE/ CD45 Percp/ CD33 APC and CD19 FITC/ CD3 PE/ CD45 Percp/ CD34 APC. Flow cytometry analyses were performed on days 0, 5, 10-15, and 30. Results on day 0 were compared with results obtained from nine adult healthy volunteers, with the same median age as the eligibility patients.

The improving remnant liver recovery was analyzed by a 64-slice Scanner CT. Pre surgery CT analysis was performed with four consecutive acquisitions (pre and post contrast medium injection). Post surgery analysis was carried out on days 10, 30 and 60, one acquisition, post contrast medium injection, during portal phase. The following parameters were used; voltage 120 kVp, current of 200-275 mAs, and section thickness of 5 mm in order to optimize liver volumetry analyses. Results were analyzed by two radiologists specialized in liver images. CT results were analyzed by Vitrea Advanced Software.

Secondary outcome measures

Patient clinical and laboratory exams were performed during the recruitment phase and on day 0 before G-CSF/NaCl 0.9% administration, and days 5, 10 and 60.

The following exams were performed: Hemoglobin (Hb); Hematocrit (HT); Leucocytes; Platelets; Albumin; Prothrombin Time/international normalized ratio (PT/INR); Activated partial

tromboplastin time/ratio (APTT/R), aspartate aminotransferase (AST) alanine amino transferase (ALT); alkaline phosphatase (Alkaline Phos); gamma glutamil transferase (GGT); urea (U); creatinine (C); glycemia (mg/dL) and ferritin.

Some clinical and laboratorial data were also analyzed post surgery on day 10: days spent in the Intensive Care Unit (ICU), bleeding volume during the surgeries, and blood usage.

Overall study start date

01/08/2008

Completion date

01/07/2015

Eligibility

Key inclusion criteria

1. Aged between 18 and 75 years
2. Controlled primary neoplasia disease
3. Absence of clinical, laboratorial and radiological evidence of tumor metastasis

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

79 patients

Key exclusion criteria

1. Chronic hepatic insufficiency
2. Hepatic encephalopathy
3. Coagulopathy
4. Presence of hepatoblastoma
5. Disseminated intravascular coagulation
5. Renal or cardiac insufficiency
5. Acute infection
6. Sepsis (defined by the criteria of the Society of Critical Care Medicine and American College of Chest Physicians, 1992)
7. Those enlisted for liver transplantation.

Date of first enrolment

01/02/2010

Date of final enrolment

01/03/2011

Locations**Countries of recruitment**

Brazil

Study participating centre**Clinic Hospital**

Rua Vital Brasil, 251

Barão Geraldo

Campinas

Brazil

13083-888

Study participating centre**Haematology Hemotherapy Centre**

Rua Carlos Chagas, 480

Barão Geraldo

Campinas

Brazil

13083-970

Sponsor information**Organisation**

State University of Campinas (Brazil)

Sponsor details

Haematology Hemotherapy Centre/Hemocentro

Rua Carlos Chagas, 480

Campinas

Brazil

13083-970

Sponsor type

University/education

Website

www.unicamp.br

ROR

<https://ror.org/04wffgt70>

Funder(s)

Funder type

Research council

Funder Name

Brazilian National Counsel of Technological and Scientific Development

Results and Publications

Publication and dissemination plan

Not provided at time of registration.

Intention to publish date

22/12/2015

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request